查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085759

肝炎檢測試劑與診斷市場：2026-2032年全球市場預測（依產品類型、檢測類型、技術、檢測方法、應用、最終用戶、肝炎類型及疾病階段分類）

Hepatitis Test Solution/Diagnosis Market by Product Type, Test Type, Technology, Mode of Testing, Application, End User, Hepatitis Type, Disease Stage - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝炎檢測解決方案/診斷市場將成長至 57.9 億美元，複合年成長率為 5.72%。

主要市場統計數據
基準年 2025 39.2億美元
預計年份：2026年 41.4億美元
預測年份 2032 57.9億美元
複合年成長率 (%) 5.72%

實施肝炎檢測方案

病毒性肝炎仍然是醫療衛生系統、實驗室和診斷設備製造商面臨的最重大感染疾病負擔之一。根據世界衛生組織（世衛組織）統計，截至2022年，全球有3.04億人患有慢性B型或C型肝炎，肝炎相關死亡人數與其他主要感染疾病的死亡人數相當。這導致肝炎檢測解決方案的需求持續旺盛，涵蓋篩檢、確診、病毒量監測、基因分型、即時檢測和檢查室自動化等各個方面。

肝炎診斷領域的變革性變化

診斷方法正從間歇性的、基於風險的檢測轉向更廣泛的人群篩檢和綜合診療路徑。在美國，疾病管制與預防中心 (CDC) 建議對成年人進行乙型和丙型肝炎普遍篩檢，而世界衛生組織 (WHO) 的指南則強調擴大診斷範圍是到 2030 年根除病毒性肝炎的核心要求。這些政策變化正在推動對高擴充性血清學檢測、快速診斷檢測和高通量分子診斷平台的需求。

人工智慧對診斷的累積影響

人工智慧 (AI) 正在提升肝炎的診斷水平，主要體現在工作流程最佳化、患者風險識別、基於影像的肝功能評估以及檢查室決策支援等方面。 AI 有助於優先識別高風險族群、識別異常肝酵素模式、支持反射性檢測策略，並縮短從篩檢到確診的等待時間。這些應用符合實證醫學原則，因為最終診斷仍然依賴檢驗的免疫檢測、分子檢測以及臨床醫生的解釋。

主要肝炎檢測市場的關鍵區域洞察

亞太地區由於人口眾多、既往周產期感染率高以及各地區疫苗接種率和新生兒疫苗接種率不均等，面臨著尤為沉重的乙型肝炎負擔。中國、印度、日本、韓國和澳洲的需求模式各不相同，涵蓋了從大規模公共篩檢和婦幼保健計畫到先進的分子監測和專家主導的肝病管理等各個方面。北美地區的特點是普遍的篩檢指南、強大的檢測能力以及與注射毒品、人口老化和治療協調工作相關的持續的丙型肝炎檢測需求。

關鍵小組對肝炎檢測需求的洞察

在東南亞國協，人口密度高、全民健康覆蓋範圍擴大以及持續開展的乙型肝炎（HBV）預防項目推動了需求成長，各國優先考慮提供價格合理的篩檢、產前檢測以及將其與婦幼保健相結合。海灣合作理事會（GCC）國家則以基礎設施主導，國家篩檢計畫、移民健康檢查、醫療旅遊和集中採購促進了高品質診斷技術的應用。在歐盟，對監測品質、統一公共衛生標準、血液安全和病毒性肝炎根除目標的重視，催生了對檢查室自動化和推廣檢測的需求。

主要國家肝炎診斷趨勢

美國在基於指南的乙型和丙型肝炎篩檢、先進的分子檢測以及大規模檢查室基礎設施方面發揮著主導作用，而加拿大則強調與公共衛生服務、原住民健康優先事項和減少危害相關的丙型肝炎檢測。墨西哥和巴西是拉丁美洲的重要市場，這得益於其龐大的人口規模、血液安全計劃、產前檢測以及不斷擴展的公共診斷系統。英國、德國、法國、義大利和西班牙擁有健全的檢測網路、國家衛生系統和公共衛生篩檢系統，俄羅斯則認為，在地域遼闊、醫療保健體系多元化的地區，對乙肝病毒和丙肝病毒的診斷需求仍然存在。

為行業領導者提供的實用建議

產業領導者應優先開發一套經過驗證、可擴展且經濟高效的肝炎檢測產品組合，涵蓋篩檢、擴充性、病毒載量監測、檢驗必要的基因分型以及治療後續觀察。產品策略應與世界衛生組織的根除目標、全民篩檢趨勢、血庫要求、產前保健、職業健康規程以及針對高風險和弱勢群體的推廣計劃保持一致。

調查方法和資料的檢驗

本調查方法整合了全球公認的衛生權威機構（包括世界衛生組織、美國疾病管制與預防中心、歐洲疾病預防控制中心、各國衛生署、監管機構、血液安全計畫以及同儕審查的臨床文獻）的二手研究數據。解讀過程中考慮了疾病負擔、篩檢建議、實驗室部署、醫療基礎設施、保險報銷、採購模式、診斷技術發展趨勢以及檢查室檢測和即時檢測的作用。

結論：肝炎診斷的策略展望

隨著世界各國政府和醫療衛生系統加強消除診斷差異，肝炎檢測解決方案領域預計將繼續保持其重要性。數億人患有慢性乙型或丙型肝炎，其中許多人仍未確診，因此，可靠的篩檢和確診檢測對於降低肝硬化、肝細胞癌、感染風險和可預防的死亡率至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肝炎檢測試劑與診斷市場：依產品類型分類

  • 裝置
    • 桌面設備
    • 高通量設備
  • 試劑盒和耗材
    • 檢測套組
    • 檢測試劑
  • 軟體服務

第8章：肝炎檢測試劑與診斷市場：依檢測類型分類

  • 血清學檢測
    • 抗原檢測
    • 抗體檢測
  • 分子和核酸檢測
  • 快速診斷檢測（RDT）
    • 橫向流動化驗
    • 即時偵測 (POC) 套件
  • 肝功能檢查（輔助診斷檢查）
    • ALT/AST 檢測
    • 膽紅素試驗
  • 基因分型和病毒量檢測

第9章：肝炎檢測試劑與診斷市場：依技術分類

  • 酵素免疫分析法（ELISA）
  • 化學冷光免疫檢測（CLIA）
  • 聚合酵素鏈鎖反應（PCR）
  • 等溫擴增
  • 側向流動免疫檢測
  • 定序技術（NGS）

第10章：肝炎檢測試劑及診斷市場：依檢測方法分類

  • 檢查室測試
  • 即時偵測 (POC)
  • 家庭檢測/自我檢測

第11章 肝炎檢測試劑與診斷市場：依應用領域分類

  • 篩檢
  • 診斷/最終診斷
  • 病毒量監測
  • 治療監測和預後
  • 流行病學監測

第12章 肝炎檢測試劑與診斷市場：依最終用戶分類

  • 血庫
  • 診斷檢查室
  • 居家醫療
  • 醫院和診所
  • 學術研究機構

第13章 肝炎檢測試劑與診斷市場：依肝炎類型分類

  • 甲型肝炎（HAV）
  • 乙型肝炎（HBV）
  • 丙型肝炎（HCV）
  • 丁型肝炎（HDV）
  • 戊型肝炎（HEV）

第14章 肝炎檢測試劑與診斷市場：依疾病階段分類

  • 急性感染檢測
  • 慢性感染的監測
  • 治療後後續觀察

第15章 肝炎檢測試劑與診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章 肝炎檢測試劑與診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 肝炎檢測試劑與診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • BioCheck, Inc.
  • bioMerieux SA
  • CTK Biotech, Inc.
  • Danaher Corporation
  • DIALAB GmbH
  • DiaSorin SpA
  • Getein Biotech, Inc.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • HU Group Holdings, Inc.
  • Hangzhou AllTest Biotech Co., Ltd.
  • Hologic, Inc.
  • HUMAN Gesellschaft fur Biochemica und Diagnostica mbH
  • InTec PRODUCTS, INC.
  • J. Mitra & Co. Pvt. Ltd.
  • Jiangsu BioPerfectus Technologies Co., Ltd.
  • Maccura Biotechnology Co., Ltd.
  • Meril Life Sciences Pvt. Ltd.
  • OraSure Technologies, Inc.
  • Premier Medical Corporation Private Limited
  • QIAGEN NV
  • QuidelOrtho Corporation
  • Revvity, Inc.
  • Roche Holding Ltd
  • Sansure Biotech Inc.
  • Seegene Inc.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shenzhen New Industries Biomedical Engineering Co., Ltd.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Transasia Bio-Medicals Ltd.
  • Tulip Diagnostics（P）Ltd.
Product Code: MRR-43127F727883

The Hepatitis Test Solution/Diagnosis Market is projected to grow by USD 5.79 billion at a CAGR of 5.72% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.92 billion
Estimated Year [2026] USD 4.14 billion
Forecast Year [2032] USD 5.79 billion
CAGR (%) 5.72%

Executive Introduction to Hepatitis Test Solutions

Viral hepatitis remains one of the most consequential infectious disease burdens for health systems, laboratories, and diagnostic manufacturers. The World Health Organization reported 304 million people living with chronic hepatitis B or C in 2022, with hepatitis-related mortality comparable to major global communicable diseases. This creates sustained demand for hepatitis test solutions spanning screening, confirmatory diagnosis, viral load monitoring, genotyping, point-of-care testing, and laboratory automation.

The hepatitis diagnosis landscape is shaped by public health screening mandates, blood safety requirements, antenatal testing, harm-reduction programs, and growing clinical adoption of nucleic acid testing. High-value sector themes include hepatitis testing, hepatitis diagnosis, HBV testing, HCV testing, liver infection diagnostics, viral hepatitis screening, molecular diagnostics, immunoassay testing, rapid diagnostic testing, and point-of-care hepatitis tests.

Transformative Shifts in the Hepatitis Diagnostics Landscape

The landscape is shifting from episodic, risk-based testing toward broader population screening and integrated care pathways. In the United States, CDC recommendations support universal adult screening for hepatitis B and hepatitis C, while WHO guidance emphasizes expanded diagnosis as a core requirement for viral hepatitis elimination by 2030. These policy changes are increasing demand for scalable serology, rapid diagnostic tests, and high-throughput molecular platforms.

Another major shift is decentralization. Hospitals and reference laboratories remain essential, but community clinics, antenatal programs, prisons, blood banks, and harm-reduction centers increasingly require faster access to reliable hepatitis diagnosis. This favors tests with simplified workflows, lower sample-volume requirements, digital result capture, reflex testing capability, and compatibility with linkage-to-care programs.

Cumulative Impact of Artificial Intelligence on Diagnosis

Artificial intelligence is strengthening hepatitis diagnosis primarily through workflow optimization, patient-risk identification, image-enabled liver assessment, and laboratory decision support. AI can help prioritize high-risk populations, flag abnormal liver enzyme patterns, support reflex testing strategies, and reduce delays between screening and confirmatory diagnosis. These applications align with evidence-based care because final diagnosis still depends on validated immunoassays, molecular tests, and clinician interpretation.

The cumulative impact of AI is expected to be operational rather than substitutive. Laboratories can use predictive analytics to improve test utilization, reduce repeat testing, anticipate reagent needs, and identify care gaps. For diagnostic developers and healthcare providers, AI-enabled platforms may support quality control, automated interpretation, and surveillance analytics, provided systems meet regulatory, privacy, cybersecurity, and clinical validation requirements.

Key Regional Insights Across Major Hepatitis Testing Markets

Asia-Pacific carries a substantial hepatitis B burden, supported by large populations, historical perinatal transmission, and uneven vaccination and birth-dose coverage in several settings. China, India, Japan, South Korea, and Australia show different demand patterns, ranging from high-volume public screening and maternal-child health programs to advanced molecular monitoring and specialist-led liver disease management. North America is characterized by universal screening guidance, strong laboratory capacity, and persistent HCV testing demand linked to injection drug use, aging cohorts, and treatment linkage initiatives.

Europe benefits from mature laboratory infrastructure, surveillance systems, and European Union public health coordination, though diagnosis gaps remain among migrants, underserved communities, incarcerated populations, and people who inject drugs. Latin America is expanding hepatitis testing through blood screening, antenatal care, and public health programs, with Brazil and Mexico anchoring regional diagnostic activity. The Middle East is supported by premarital screening, migrant health programs, centralized healthcare investment, and high-capacity hospital networks, particularly in GCC markets. Africa faces high HBV prevalence in several countries and needs affordable rapid testing, timely birth-dose linkage, safe blood screening, and decentralized molecular access to improve diagnosis and treatment initiation.

Key Group Insights for Hepatitis Testing Demand

ASEAN demand is supported by high population density, expanding universal health coverage, and ongoing HBV prevention programs, with countries prioritizing affordable screening, antenatal testing, and maternal-child health integration. The GCC is more infrastructure-led, with national screening programs, migrant health assessments, medical tourism, and centralized procurement supporting premium diagnostic adoption. The European Union emphasizes surveillance quality, harmonized public health standards, blood safety, and viral hepatitis elimination targets, creating demand for both laboratory automation and outreach testing.

BRICS countries represent a high-volume diagnostic environment because Brazil, Russia, India, China, and South Africa combine sizable populations, varied hepatitis burdens, and expanding domestic diagnostic capabilities. G7 markets drive innovation through regulatory rigor, reimbursement maturity, integrated laboratory networks, and adoption of high-throughput molecular diagnostics. NATO countries overlap heavily with high-income European and North American systems, where military health services, blood safety standards, deployable medical capabilities, and infectious disease readiness reinforce demand for reliable hepatitis testing.

Key Country Insights in Hepatitis Diagnosis

The United States leads in guideline-driven HBV and HCV screening, advanced molecular testing, and large-scale laboratory infrastructure, while Canada emphasizes public health access, Indigenous health priorities, and harm-reduction-linked HCV testing. Mexico and Brazil are important Latin American markets due to population size, blood safety programs, antenatal testing, and expanding public diagnostics. The United Kingdom, Germany, France, Italy, and Spain maintain strong laboratory networks, national health systems, and public health screening capacity, while Russia shows continued need for HBV and HCV diagnosis across a broad geography and diverse care settings.

China and India are central to global hepatitis testing because of their large populations and substantial chronic HBV burden, with rising demand for affordable immunoassays, rapid screening, and molecular confirmation. Japan, Australia, and South Korea represent advanced Asia-Pacific markets with mature screening systems, high-quality laboratories, and strong clinical monitoring for chronic liver disease. Across these countries, progress depends on earlier diagnosis, reflex testing, treatment linkage, digital reporting, and integration of hepatitis screening into routine primary care, antenatal services, blood safety systems, and community outreach.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated, scalable, and cost-efficient hepatitis testing portfolios that cover screening, confirmation, viral load monitoring, genotyping where clinically required, and treatment follow-up. Product strategies should align with WHO elimination goals, universal screening trends, blood bank requirements, antenatal care, occupational health protocols, and outreach programs for high-risk and underserved populations.

Organizations should invest in point-of-care and near-patient testing where access barriers remain high, while maintaining high-throughput platforms for centralized laboratories. Partnerships with public health agencies, payers, non-governmental organizations, and digital health providers can improve linkage to care. Leaders should also strengthen regulatory evidence, quality management, local supply resilience, training programs, and AI-enabled workflow tools that improve laboratory productivity without compromising diagnostic accuracy.

Research Methodology and Data Validation

The research methodology integrates secondary research from globally recognized health authorities, including WHO, CDC, ECDC, national health ministries, regulatory agencies, blood safety programs, and peer-reviewed clinical literature. Interpretation considers disease burden, screening recommendations, test adoption, healthcare infrastructure, reimbursement, procurement models, diagnostic technology trends, and the role of laboratory and point-of-care testing.

The analysis is structured to support executive decision-making across product strategy, regional expansion, competitive positioning, and commercialization. Insights are validated through triangulation of epidemiological evidence, policy direction, laboratory practice patterns, regulatory guidance, and technology adoption indicators, ensuring that conclusions remain data-backed and relevant to the hepatitis test solution and diagnosis landscape.

Conclusion: Strategic Outlook for Hepatitis Diagnostics

The hepatitis test solution landscape is positioned for durable relevance as governments and healthcare systems intensify efforts to close diagnosis gaps. With hundreds of millions of people living with chronic hepatitis B or C and many still undiagnosed, reliable screening and confirmatory testing remain essential to reducing liver cirrhosis, hepatocellular carcinoma, transmission risk, and preventable mortality.

Future leadership will depend on accessible testing, laboratory efficiency, regulatory quality, affordability, and faster linkage to care. Organizations that combine validated immunoassay and molecular diagnostics with decentralized access, digital reporting, and AI-supported workflow intelligence will be best positioned to support global viral hepatitis elimination objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hepatitis Test Solution/Diagnosis Market, by Product Type

  • 7.1. Instruments
    • 7.1.1. Bench-Top Instruments
    • 7.1.2. High-Throughput Instruments
  • 7.2. Kits & Consumables
    • 7.2.1. Test Kits
    • 7.2.2. Assay Reagents
  • 7.3. Software & Services

8. Hepatitis Test Solution/Diagnosis Market, by Test Type

  • 8.1. Serological Tests
    • 8.1.1. Antigen Tests
    • 8.1.2. Antibody Tests
  • 8.2. Molecular / Nucleic Acid Tests
  • 8.3. Rapid Diagnostic Tests (RDTs)
    • 8.3.1. Lateral Flow Assays
    • 8.3.2. Point-of-Care (POC) Kits
  • 8.4. Liver Function Tests (Supportive Diagnostics)
    • 8.4.1. ALT / AST Tests
    • 8.4.2. Bilirubin Tests
  • 8.5. Genotyping & Viral Load Testing

9. Hepatitis Test Solution/Diagnosis Market, by Technology

  • 9.1. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 9.2. Chemiluminescent Immunoassay (CLIA)
  • 9.3. Polymerase Chain Reaction (PCR)
  • 9.4. Isothermal Amplification
  • 9.5. Lateral Flow Immunoassay
  • 9.6. Sequencing Technologies (NGS)

10. Hepatitis Test Solution/Diagnosis Market, by Mode of Testing

  • 10.1. Laboratory-Based Testing
  • 10.2. Point-of-Care (POC) Testing
  • 10.3. Home-Based / Self-Testing

11. Hepatitis Test Solution/Diagnosis Market, by Application

  • 11.1. Screening
  • 11.2. Diagnosis / Confirmation
  • 11.3. Viral Load Monitoring
  • 11.4. Treatment Monitoring & Prognosis
  • 11.5. Epidemiological Surveillance

12. Hepatitis Test Solution/Diagnosis Market, by End User

  • 12.1. Blood Banks
  • 12.2. Diagnostic Laboratories
  • 12.3. Home Care Settings
  • 12.4. Hospitals & Clinics
  • 12.5. Academic & Research Institutes

13. Hepatitis Test Solution/Diagnosis Market, by Hepatitis Type

  • 13.1. Hepatitis A (HAV)
  • 13.2. Hepatitis B (HBV)
  • 13.3. Hepatitis C (HCV)
  • 13.4. Hepatitis D (HDV)
  • 13.5. Hepatitis E (HEV)

14. Hepatitis Test Solution/Diagnosis Market, by Disease Stage

  • 14.1. Acute Infection Testing
  • 14.2. Chronic Infection Monitoring
  • 14.3. Post-Treatment Monitoring

15. Hepatitis Test Solution/Diagnosis Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Hepatitis Test Solution/Diagnosis Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Hepatitis Test Solution/Diagnosis Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Abbott Laboratories
  • 19.2. ACON Laboratories, Inc.
  • 19.3. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
  • 19.4. Bio-Rad Laboratories, Inc.
  • 19.5. BioCheck, Inc.
  • 19.6. bioMerieux SA
  • 19.7. CTK Biotech, Inc.
  • 19.8. Danaher Corporation
  • 19.9. DIALAB GmbH
  • 19.10. DiaSorin S.p.A.
  • 19.11. Getein Biotech, Inc.
  • 19.12. Guangzhou Wondfo Biotech Co., Ltd.
  • 19.13. H.U. Group Holdings, Inc.
  • 19.14. Hangzhou AllTest Biotech Co., Ltd.
  • 19.15. Hologic, Inc.
  • 19.16. HUMAN Gesellschaft fur Biochemica und Diagnostica mbH
  • 19.17. InTec PRODUCTS, INC.
  • 19.18. J. Mitra & Co. Pvt. Ltd.
  • 19.19. Jiangsu BioPerfectus Technologies Co., Ltd.
  • 19.20. Maccura Biotechnology Co., Ltd.
  • 19.21. Meril Life Sciences Pvt. Ltd.
  • 19.22. OraSure Technologies, Inc.
  • 19.23. Premier Medical Corporation Private Limited
  • 19.24. QIAGEN N.V.
  • 19.25. QuidelOrtho Corporation
  • 19.26. Revvity, Inc.
  • 19.27. Roche Holding Ltd
  • 19.28. Sansure Biotech Inc.
  • 19.29. Seegene Inc.
  • 19.30. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 19.31. Shenzhen New Industries Biomedical Engineering Co., Ltd.
  • 19.32. Siemens Healthineers AG
  • 19.33. Sysmex Corporation
  • 19.34. Transasia Bio-Medicals Ltd.
  • 19.35. Tulip Diagnostics (P) Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BENCH-TOP INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BENCH-TOP INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BENCH-TOP INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HIGH-THROUGHPUT INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HIGH-THROUGHPUT INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIGH-THROUGHPUT INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL KITS & CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL KITS & CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL KITS & CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ASSAY REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASSAY REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ASSAY REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SEROLOGICAL TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SEROLOGICAL TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEROLOGICAL TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIGEN TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIGEN TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIGEN TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBODY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MOLECULAR / NUCLEIC ACID TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLECULAR / NUCLEIC ACID TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MOLECULAR / NUCLEIC ACID TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RAPID DIAGNOSTIC TESTS (RDTS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RAPID DIAGNOSTIC TESTS (RDTS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RAPID DIAGNOSTIC TESTS (RDTS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LATERAL FLOW ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LATERAL FLOW ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LATERAL FLOW ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POINT-OF-CARE (POC) KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POINT-OF-CARE (POC) KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POINT-OF-CARE (POC) KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALT / AST TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALT / AST TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALT / AST TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BILIRUBIN TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BILIRUBIN TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BILIRUBIN TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOTYPING & VIRAL LOAD TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENOTYPING & VIRAL LOAD TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOTYPING & VIRAL LOAD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHEMILUMINESCENT IMMUNOASSAY (CLIA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHEMILUMINESCENT IMMUNOASSAY (CLIA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHEMILUMINESCENT IMMUNOASSAY (CLIA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SEQUENCING TECHNOLOGIES (NGS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SEQUENCING TECHNOLOGIES (NGS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SEQUENCING TECHNOLOGIES (NGS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LABORATORY-BASED TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LABORATORY-BASED TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LABORATORY-BASED TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POINT-OF-CARE (POC) TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POINT-OF-CARE (POC) TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POINT-OF-CARE (POC) TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOME-BASED / SELF-TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOME-BASED / SELF-TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOME-BASED / SELF-TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIAGNOSIS / CONFIRMATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIAGNOSIS / CONFIRMATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIAGNOSIS / CONFIRMATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL LOAD MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL LOAD MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL LOAD MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TREATMENT MONITORING & PROGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TREATMENT MONITORING & PROGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TREATMENT MONITORING & PROGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL EPIDEMIOLOGICAL SURVEILLANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL EPIDEMIOLOGICAL SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL EPIDEMIOLOGICAL SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD BANKS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD BANKS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD BANKS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HEPATITIS A (HAV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEPATITIS A (HAV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HEPATITIS A (HAV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEPATITIS B (HBV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HEPATITIS B (HBV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEPATITIS B (HBV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HEPATITIS C (HCV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEPATITIS C (HCV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HEPATITIS C (HCV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEPATITIS D (HDV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HEPATITIS D (HDV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEPATITIS D (HDV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HEPATITIS E (HEV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEPATITIS E (HEV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HEPATITIS E (HEV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ACUTE INFECTION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ACUTE INFECTION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ACUTE INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHRONIC INFECTION MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CHRONIC INFECTION MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHRONIC INFECTION MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL POST-TREATMENT MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL POST-TREATMENT MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL POST-TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 245. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 248. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 249. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 252. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 253. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 255. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 280. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 281. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 287. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 291. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 293. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 294. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 295. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 297. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 301. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 304. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 305. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 308. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 309. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MODE OF TESTING, 2018-2032 (USD MILLION)
  • TABLE 311. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 315. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY LIVER FUNCTION TESTS (SUPPORTIVE DIAGNOSTICS), 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES HEPATITIS TEST SOLUTI